Alkermes plc Interest Expense 2011-2026 | ALKS

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Alkermes plc

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
4.47 M	3.24 M	-425 K	2.12 M	11.2 M	8.66 M	13.6 M	15.4 M	12 M	14.9 M	13.2 M	13.4 M	49 M	28.1 M	3.3 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
49 M	-425 K	12.8 M

Quarterly Interest Expense Alkermes plc

2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	1.56 M	-	558 K	5.95 M	182 K	-	149 K	5.68 M	5.29 M	-	3.55 M	2.37 M	2.35 M	-	2.44 M	2.41 M	3.97 M	-	1.81 M	2.12 M	2.86 M	-	3.38 M	3.52 M	3.5 M	-	3.35 M	3.13 M	5.49 M	-	3.13 M	2.92 M	2.76 M	-	3.38 M	3.32 M	3.3 M	-	3.32 M	3.32 M	3.29 M	-	3.36 M	3.38 M	3.36 M	-	3.48 M	3.47 M	11.5 M	4.7 M	22.6 M	32.8 M	-	10.5 M	18 M	7.56 M	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
32.8 M	149 K	5.09 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
ACADIA Pharmaceuticals ACAD	1.82 M	$ 22.56	2.13 %	$ 3.74 B	USA
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Akebia Therapeutics AKBA	58 K	$ 1.43	3.62 %	$ 368 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Alnylam Pharmaceuticals ALNY	5.2 M	$ 327.25	2.42 %	$ 42.9 B	USA
Aytu BioScience AYTU	-512 K	$ 2.66	3.5 %	$ 16.7 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.9	3.7 %	$ 9.38 B	Australia
CymaBay Therapeutics CBAY	18.9 M	-	-	$ 3.45 B	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Amphastar Pharmaceuticals AMPH	23 K	$ 20.4	-0.87 %	$ 954 M	USA
Aquestive Therapeutics AQST	6.55 M	$ 4.18	1.21 %	$ 447 M	USA
Avid Bioservices CDMO	4.34 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	5.81 M	-	-	$ 1.41 B	USA
Arcutis Biotherapeutics ARQT	443 K	$ 24.61	5.76 %	$ 3.13 B	USA
Cabaletta Bio CABA	2 M	$ 3.09	0.65 %	$ 310 M	USA
Checkpoint Therapeutics CKPT	344 K	-	-	$ 169 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Concert Pharmaceuticals CNCE	-309 K	-	-	$ 401 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.49	9.56 %	$ 397 M	Britain
CTI BioPharma Corp. CTIC	13.1 M	-	-	$ 1.2 B	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	16.4 M	-	-	$ 2.18 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Dynavax Technologies Corporation DVAX	293 K	-	-	$ 2.02 B	USA
Forte Biosciences FBRX	-396 K	$ 26.27	0.38 %	$ 340 M	USA
Akari Therapeutics, Plc AKTX	100 K	$ 3.88	2.11 %	$ 261 B	Britain
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA